Business
Marina Biotech to Present A Late Breaking Poster on the Safety and Tolerability of CEQ508 for FAP at the Society of Toxicology 56th Annual Meeting on March 16
Marina Biotech to Present A Late Breaking Poster on the Safety and Tolerability of CEQ508 for FAP at the Society of Toxicology 56th Annual Meeting on March 16.
About this update from Adhera Therapeutics Inc.
[{"type":"text","content":"\n \n \n Marina Biotech to Present A Late Breaking Poster on the Safety and Tolerability of CEQ508 for FAP at the Society of Toxicology 56th Annual Meeting on March 16\n \n \nMarina Biotech to Present A Late Breaking Poster on the Safety and Tolerability of CEQ508 for FAP at the Society of Toxicology 56th Annual Meeting on March 16\n \n CITY OF INDUSTRY, CA--(Marketwired - Mar 13, 2017) - Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, today announced that a new poster1 on the safety and tolerability findings of the Company's CEQ508, RNAi therapeutic in Familial Adenomatous Polyposis (FAP) will be presented at the Society of Toxicology 56th Annual Meeting to be held at the Baltimore Convention Center in Baltimore, MD on March 12-16, 2017. \n On March 16 at 8:30am E.T., Dr. Osmond D'Cruz, co-author of the abstract, will present the findings of the safety and tolerability of an RNAi therapeutic in Familial Adenomatous Polyposis (START-FAP) proof of concept clinical trial with CEQ508. The late breaking poster outlines a dose escalating Phase 1 trial conducted with with daily, oral administration of CEQ508 over 28 days of FAP patients. \n Joseph Ramelli, CEO of Marina Biotech, stated, \"The completion of this trial is a great milestone for Marina Biotech. Our clinical results continue to prove that our proprietary tkRNAi delivery platform is a safe and effective oral delivery of siRNA. This is the only oral delivery platform for oligotherapeutics and we look forward to continuing development of CEQ508 for FAP as well as expansion of the platform to other indications.\" \n 1\"Safety and Tolerability of Live-Attenuated Bacteria CEQ508 Engineered to Produce and Deliver Short-Hairpin RNA-Mediated Knockdown of β Catenin in the Gastrointestinal Mucosa of Patients with Familial Adenomatous Polyposis, authored by O. J. D'Cruz, L. Hwang, K. Ng, A. T. Fong, D. Nam, W. Wang, V. Trieu.\"\n About Marina Biotech\n Marina Biotech is a biotechnology company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension, and cancer. Our pipeline includes combination therapies of oligonucleotide-based therapeutics and small mo...